3.92
+0.09(+2.35%)
Currency In USD
| Previous Close | 3.83 |
| Open | 3.9 |
| Day High | 4.14 |
| Day Low | 3.85 |
| 52-Week High | 5.62 |
| 52-Week Low | 1.11 |
| Volume | 2.04M |
| Average Volume | 3.69M |
| Market Cap | 527.22M |
| PE | -2.43 |
| EPS | -1.61 |
| Moving Average 50 Days | 2.66 |
| Moving Average 200 Days | 2.67 |
| Change | 0.09 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $255.04 as of July 31, 2025 at a share price of $3.92. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 2 years ago, it would be worth $260.12 as of July 31, 2025 at a share price of $3.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine Announces Pricing of Public Offering
GlobeNewswire Inc.
10 hours ago
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritt
Prime Medicine Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Yesterday at 8:01 PM GMT
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an und
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
GlobeNewswire Inc.
Jul 16, 2025 11:00 AM GMT
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot